GNS vs. BTG, ABC, ONT, ERGO, PRTC, SLN, OXB, HZD, VRP, and BVXP
Should you be buying Genus stock or one of its competitors? The main competitors of Genus include BTG (BTG), Abcam (ABC), Oxford Nanopore Technologies (ONT), Ergomed (ERGO), PureTech Health (PRTC), Silence Therapeutics (SLN), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), and Bioventix (BVXP). These companies are all part of the "biotechnology" industry.
BTG (LON:BTG) and Genus (LON:GNS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.
78.5% of Genus shares are held by institutional investors. 0.7% of Genus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, BTG had 4 more articles in the media than Genus. MarketBeat recorded 4 mentions for BTG and 0 mentions for Genus. Genus' average media sentiment score of 0.04 beat BTG's score of 0.00 indicating that BTG is being referred to more favorably in the media.
Genus has a net margin of 4.96% compared to Genus' net margin of 0.00%. BTG's return on equity of 5.27% beat Genus' return on equity.
Genus has lower revenue, but higher earnings than BTG. BTG is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.
BTG received 269 more outperform votes than Genus when rated by MarketBeat users. Likewise, 73.95% of users gave BTG an outperform vote while only 70.56% of users gave Genus an outperform vote.
Summary
BTG and Genus tied by winning 6 of the 12 factors compared between the two stocks.
Get Genus News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
